← All trials
NCT06311578
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 10, 2024
- Primary completion
- Nov 8, 2028
- Completion date
- Nov 30, 2033
- First posted
- Mar 15, 2024
- Last posted
- Oct 24, 2024
- Enrollment
- 96
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johnson and JohnsonLead sponsor
- Johnson and JohnsonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.